ATE212550T1 - Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung - Google Patents

Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung

Info

Publication number
ATE212550T1
ATE212550T1 AT98937738T AT98937738T ATE212550T1 AT E212550 T1 ATE212550 T1 AT E212550T1 AT 98937738 T AT98937738 T AT 98937738T AT 98937738 T AT98937738 T AT 98937738T AT E212550 T1 ATE212550 T1 AT E212550T1
Authority
AT
Austria
Prior art keywords
hours
tiagabine
active ingredients
preparations containing
medicinal preparations
Prior art date
Application number
AT98937738T
Other languages
German (de)
English (en)
Inventor
Maurice Joseph Anthony Clancy
Michelle Caulfield
Kenneth Iain Cumming
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26320083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE212550(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IE19970588A external-priority patent/IE970588A1/en
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Application granted granted Critical
Publication of ATE212550T1 publication Critical patent/ATE212550T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT98937738T 1997-08-01 1998-07-30 Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung ATE212550T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5443297P 1997-08-01 1997-08-01
IE19970588A IE970588A1 (en) 1997-08-01 1997-08-08 Controlled release pharmaceutical compositions containing tiagabine
PCT/IE1998/000067 WO1999006045A1 (en) 1997-08-01 1998-07-30 Controlled release pharmaceutical compositions containing tiagabine

Publications (1)

Publication Number Publication Date
ATE212550T1 true ATE212550T1 (de) 2002-02-15

Family

ID=26320083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98937738T ATE212550T1 (de) 1997-08-01 1998-07-30 Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung

Country Status (10)

Country Link
EP (1) EP0991409B1 (https=)
JP (1) JP2001511450A (https=)
AT (1) ATE212550T1 (https=)
AU (1) AU8643698A (https=)
CA (1) CA2299464C (https=)
DE (1) DE69803670T2 (https=)
DK (1) DK0991409T3 (https=)
ES (1) ES2172179T3 (https=)
PT (1) PT991409E (https=)
WO (1) WO1999006045A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002325404B2 (en) * 1998-01-22 2006-02-02 Abbott Laboratories Extended Release Tiagabine Formulations with Reduced Side-effects
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
RU2220715C2 (ru) * 1999-08-04 2004-01-10 Яманоути Фармасьютикал Ко., Лтд. Стабильная пероральная, образующая гидрогель, фармацевтическая композиция, способ ее получения, способ предотвращения изменений высвобождения лекарственного средства, способ увеличения физической стабильности пероральной композиции
KR100510270B1 (ko) * 2002-11-29 2005-08-26 센츄론(주) 펠렛타이저를 이용한 서방성 제제의 제조방법
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
WO2004082615A2 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5750140A (en) * 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
MX9708394A (es) * 1995-05-05 1998-02-28 Novo Nordisk As Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
EP0912091B1 (en) * 1996-05-24 2007-12-19 Smithkline Beecham Corporation Use of gaba uptake inhibitors as anti-tussive agents
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders

Also Published As

Publication number Publication date
EP0991409A1 (en) 2000-04-12
EP0991409B1 (en) 2002-01-30
DK0991409T3 (da) 2002-03-25
CA2299464C (en) 2009-02-17
WO1999006045A1 (en) 1999-02-11
DE69803670D1 (de) 2002-03-14
AU8643698A (en) 1999-02-22
DE69803670T2 (de) 2002-11-21
JP2001511450A (ja) 2001-08-14
PT991409E (pt) 2002-06-28
CA2299464A1 (en) 1999-02-11
ES2172179T3 (es) 2002-09-16

Similar Documents

Publication Publication Date Title
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
YU49495B (sh) Formulacije oksikodona sa kontrolisanim otpuštanjem i njihova upotreba
IL119627A0 (en) Controlled-release pharmaceutical preparations
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
NO944565L (no) Preparat med regulert frigjörelse som inneholder et morfinsalt
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
EP1283054A4 (en) MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
EP0724885A4 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION CONTAINING THE SAME
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
DE60126433D1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
BR0211198A (pt) Composições farmacêuticas e seu uso
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
MY130098A (en) Local drug delivery film for periodontal treatment
AP2003002763A0 (en) Controlled release formulations for oral administration
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner